Please upgrade your Flash Player Tagged in: Actions and defenses, Administrative fees, Administrative procedure, Administrative remedies, Africa (Sub-Saharan), Australia, Austria, Belgium, Budgets, Business, Business records, Canada, Congress, Congressional reporting requirements, Consumer education, Consumer protection, Consumers, Damages, Denmark, Department of Health and Human Services, Drug approvals, Drug industry, Drugs, East Asia, Electronic government information, Europe, Evidence (Law), Executive departments, Federal Trade Commission, Federal-state relations, Finland, France, Germany, Government information, Government paperwork, Government publicity, Governmental investigations, Greece, Iceland, Identification devices, Import restrictions, Imports, Independent regulatory commissions, Injunctions, Intellectual property, Internet, Ireland, Israel, Italy, Japan, Labeling, Law, Licenses, Liechtenstein, Limitation of actions, Luxembourg, Medical care, Medicine, Netherlands, New Zealand, Norway, Oceania, Packaging, Parties to actions, Patent infringement, Patents, Pharmacies, Pharmacists, Portugal, Prescription pricing, Price discrimination, Product counterfeiting, Product safety, Punitive damages, Restrictive trade practices, South Africa, Spain, State and local government, Sweden, Switzerland, Technology, Telecommunication, Telephone, Trade, United Kingdom, Web sites, Wholesale trade
Latest Update: Monday, December, 01st 2008
A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs, and for other purposes. 1/10/2007--Introduced. Pharmaceutical Market Access Act of 2007 - Amends the Federal Food, Drug, and Cosmetic Act to require the Secretary of Health and Human Services to promulgate regulations permitting pharmacists, pharmacies, and wholesalers to import qualifying drugs from certain countries into the United States. Sets forth registration requirements for exporters. Requires the Secretary to: (1) educate consumers with regard to the availability of qualifying drugs for import for personal use; (2) inspect the facilities and records of importers and registered exporters to ensure compliance with this Act; and (3) establish a registration fee program to collect an annual fee from registered exporters. Deems a prescription drug to be misbranded unless the packaging of such drug complies with the requirements for counterfeit-resistant [...] show full description
- 01/10/2007 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
|
Important People
Latest News
Searching for articles...
|
